Piramal Pharma posts Rs 99 crore loss in Q2FY26 weighed down by CDMO business
Published on: Nov. 5, 2025, 10:43 p.m. | Source: Moneycontrol
The company attributed the loss to decline to inventory destocking by a key customer in a large on-patent CDMO order and slower order inflows amid inconsistent recovery in US biopharma funding.
